Semalutide, glucagon sida peptide (GLP-1) agonist receptor, ayaa loo oggolaaday daawaynta nooca 2aad ee sonkorowga. Somaglutide waxaa soo saartay Novo Nordisk 2012 iyada oo ah beddelka muddada dheer ee Liraglutide. Marka la barbardhigo Liraglutide iyo daawooyinka kale ee Sonkorowga, mid ka mid ah faa'iidooyinka Somaglutide waa in ay leedahay waqti dheer oo ficil ah, sidaas darteed toddobaadkii hal mar ayaa ku filan in lagu duro. Bishii Disembar 2017, Maamulka Cunnada iyo Dawooyinka ee Mareykanka (FDA) ayaa oggolaaday nooca duritaanka somalutide. Tijaabo caafimaad oo wajigii hore ee II ah ayaa lagu ogaaday in Somaglutide ay hoos u dhigtay miisaanka bukaanada nooca 2aad ee xanuunka macaanka iyo dadka cayilan, miisaanka dhimista ayaa loo arkaa inay sabab u tahay hoos u dhigista tamarta qaadashada ee ay sababtay dhimista rabitaanka cuntada.